Table 2 .
Correlation between the changes in SUVmax in 68Ga-PRGD2 PET/CT and 18F-FDG PET/CT and the changes in clinical parameters of patients with RA (n=12) before and after 3-month treatment
| ΔSUVmax of 68Ga-PRGD2 | ΔSUVmax of 18F-FDG | |||
|---|---|---|---|---|
| r | p Value | r | p Value | |
| ΔVAS | 0.39 | 0.215 | 0.65 | 0.021 |
| ΔPtGA | 0.62 | 0.033 | 0.61 | 0.034 |
| ΔPyGA | 0.60 | 0.040 | 0.72 | 0.009 |
| ΔcDAI | 0.60 | 0.039 | 0.52 | 0.083 |
Δ, changes between the baseline and the post-treatment evaluation; cDAI, clinical disease activity index; r, correlation coefficient; PET, positron emission tomography; PtGA, patient's global assessment of overall well-being; PyGA, physician's global assessment; RA, rheumatoid arthritis; SUVmax, maximal standardised uptake value of a tracer; VAS, visual analogue scale of joint pain.